Compare First Solar, Inc. (FSLR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? First Solar, Inc. trades at $177.79 (market cap $19.22B), while Vertex Pharmaceuticals Incorporated trades at $510.72 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.6× First Solar, Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 75 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FSLR | VRTX | |
|---|---|---|
Market Cap | $19.22B | $127.55B |
Volume | 2,067,793 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $318.30 | $557.96 |
52-Week Low | $172.11 | $407.37 |
Typical Hold Time | 75 Days | 120 Days |
Enterprise Value | $17.69B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $180.13, up 0.18% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 32.47% net income margin and trades at a P/E of 11.03, below industry averages. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. Analyst consensus is a Moderate Buy with a $267.59 price target, signaling significant upside potential despite recent sector-wide pressures and high put option activity noted in early October 2026.
The outlook for FSLR is mixed: strong earnings growth and attractive valuation support long-term upside, but near-term risks include solar sector volatility, rising borrowing costs, and patent litigation. Investors face a divergence between bullish fundamentals and bearish technicals, with the stock trading 33% below analyst targets. Key catalysts are Q3 2026 earnings and resolution of legal challenges, while headwinds include interest rate sensitivity and competitive pressures.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
